Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Multinational PIII Study of Revlimid for Follicular Lymphoma Starts in Japan: Celgene
February 24, 2014
- Sanofi to Begin Standalone Generic Operation in Japan
February 24, 2014
- Over 90% of Drug Makers Increasing Sales Rep Calls to Wholesalers Due to Imposed Restrictions
February 24, 2014
- ASKA Launches Leuplin Generic
February 21, 2014
- Diabetes Drug Sales Up 10% in 2013 Japan Market, Spurred by DPP-4 Inhibitors: IMS
February 21, 2014
- Plavix Tops Japan Ethical Drug Ranking, Sales Leap 14%: IMS
February 21, 2014
- US FDA Approves Droxidopa: DSP
February 20, 2014
- MTPC, Daiichi Sankyo Aim to Boost Sales of Struggling Tenelia
February 20, 2014
- RaQualia, Nagoya University Sign Industry-Academia Partnership Deal
February 20, 2014
- Future Relationship of Nichi-Iko and Sanofi in Question with Discontinuation of Biosimilar Codevelopment; Will They Continue to Work Together for Second AG?
February 20, 2014
- Astellas, AVEO Jettison Joint Development of Anticancer Agent Tivozanib
February 19, 2014
- Fujifilm Accepts Subscription Rights to J-TEC’s New Shares at 540 Million Yen, Commissioning Regenerative Medicine Products
February 19, 2014
- Eiken Chemical Taps Sales Division Head as New President
February 18, 2014
- US Biotech Acucela Makes Debut on TSE’s Mothers Market
February 18, 2014
- MTPC, JB to End Copromotion of Blood Plasma Products
February 18, 2014
- Nissan Chemical Sues Three More Generic Makers over Livalo Patent Infringement
February 18, 2014
- Daiichi Sankyo, UMN Pharma Sign Collaborative Research Deal for Norovirus Vaccine
February 18, 2014
- Blopress AGs Approved, Yet Blurry Prospect for Their June Listing
February 17, 2014
- Kissei, Alteogen Agree on Business Collaboration for Biosimilar Development
February 17, 2014
- LEO Pharma’s New Japan Head Takes Office
February 17, 2014
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…